A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer
Clinical Lung Cancer · 2023
DOI: 10.1016/j.cllc.2023.01.009 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2023. Verfasst von Wade T Iams und 17 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University Medical Center, Nashville, TN. Electronic address: wade.t.iams@vumc.org. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Comprehensive Cancer Network, Amgen.
Abstract (Originalsprache)
BACKGROUND: On May 28, 2021, the United States Food and Drug Administration (FDA) granted accelerated approval to sotorasib for second-line or later treatment of patients with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer (NSCLC). This was the first FDA-approved targeted therapy for this patient population. Due to a paucity of real world data describing clinical outcomes in patients with locally advanced or metastatic KRAS G12C mutated NSCLC in the second-line or later, we sought to compile a large, academic medical center-based historical dataset to clarify clinical outcomes in this patient population. MATERIALS AND METHODS: The clinical outcomes of 396 patients with stage IV (n = 268, 68%) or recurrent, metastatic (n = 128, 32%) KRAS G12C mutant NSCLC were evaluated in this multicenter retrospective chart review conducted through the Academic Thoracic Oncology Medical Investigator's Consortium (ATOMIC). Patients treated at 13 sites in the United States and Canada and diagnosed between 2006 and 2020 (30% 2006-2015, 70% 2016-2020) were included. Primary outcomes included real-world PFS (rwPFS) and overall survival (OS) from time of stage IV or metastatic diagnosis, with particular interest in patients treated with second-line docetaxel-containing regimens, as well as clinical outcomes in the known presence or absence of STK11 or KEAP1 comutations. RESULTS: Among all patients with stage IV or recurrent, metastatic KRAS G12C mutant NSCLC (n = 201 with KRAS G12C confirmed prior to first line systemic therapy), the median first-line rwPFS was 9.3 months (95% CI, 7.3-11.8 months) and median OS was 16.8 months (95% CI, 12.7-22.3 months). In this historical dataset, first line systemic therapy among these 201 patients included platinum doublet alone (44%), PD-(L)1 inhibitor monotherapy (30%), platinum doublet chemotherapy plus PD-(L)1 inhibitor (18%), and other regimens (8%). Among patients with documented second-line systemic therapy (n = 123), the second-line median rwPFS was 8.3 months (95% CI, 6.1-11.9 months), with median rwPFS 4.6 months (95% CI, 1.4-NA) among 10 docetaxel-treated patients (9 received docetaxel and 1 received docetaxel plus ramucirumab). Within the total study population, 49 patients (12%) had a co-occurring STK11 mutation and 3 (1%) had a co-occurring KEAP1 mutation. Among the 49 patients with a co-occurring KRAS G12C and STK11 mutation, median rwPFS on first-line systemic therapy (n = 23) was 6.0 months (95% CI, 4.7-NA), and median OS was 14.0 months (95% CI, 10.8-35.3 months). CONCLUSION: In this large, multicenter retrospective chart review of patients with KRAS G12C mutant NSCLC we observed a relatively short median rwPFS of 4.6 months among 10 patients with KRAS G12C mutant NSCLC treated with docetaxel with or without ramucirumab in the second-line setting, which aligns with the recently reported CodeBreak 200 dataset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanderbilt University Medical Center, Nashville, TN. Electronic address: wade.t.iams@vumc.org.
- Vanderbilt University Medical Center, Nashville, TN.
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
- University of Chicago, Chicago, IL.
- New York University, NY, NY.
- University of Pennsylvania, Philadelphia, PA.
Förderung
- NCI NIH HHS
- National Comprehensive Cancer Network
- Amgen
Zitieren
APA
Iams, W. T., Balbach, M. L., Phillips, S., Sacher, A., Bestvina, C., Velcheti, V., Wang, X., Marmarelis, M. E., Sethakorn, N., Leal, T., Sackstein, P. E., Kim, C., Robinson, M. A., Mehta, K., Hsu, R., Nieva, J., Patil, T., & Camidge, D. R. (2023). A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2023.01.009
Vancouver
Iams WT, Balbach ML, Phillips S, Sacher A, Bestvina C, Velcheti V, et al. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer. Clinical Lung Cancer. 2023. doi:10.1016/j.cllc.2023.01.009
BibTeX
@article{Iams2023,
author = {Iams, Wade T and Balbach, Meridith L and Phillips, Sharon and Sacher, Adrian and Bestvina, Christine and Velcheti, Vamsidhar and Wang, Xiao and Marmarelis, Melina E and Sethakorn, Nan and Leal, Ticiana and Sackstein, Paul E and Kim, Chul and Robinson, Md Andrew and Mehta, Kathan and Hsu, Robert and Nieva, Jorge and Patil, Tejas and Camidge, D Ross},
title = {A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer},
journal = {Clinical Lung Cancer},
year = {2023},
doi = {10.1016/j.cllc.2023.01.009}
}
EUVIMED